Tags

Type your tag names separated by a space and hit enter

Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review.
Pharmaceuticals (Basel). 2021 Jul 28; 14(8)P

Abstract

Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in developing new drugs, some drugs already approved for other diseases or with efficacy against SARS and MERS, have been used in patients with COVID-19. This systematic review aims to summarize evidence on the efficacy and safety of five antivirals applied to patients with COVID-19, that have proven to be effective either in vitro studies or in studies on SARS-CoV and MERS.; An intensive search of different databases (Pub Med, WoS, MEDLINE and Cochrane COVID-19 Study Register) has been carried out until the end of April 2021. This systematic review has been conducted according to the PRISMA statement. From each of the included studies, the characteristics of the intervention and comparison groups, demographic data and results were extracted independently; Remdesivir is well tolerated and helps to accelerate clinical improvement but is ineffective in reducing mortality. Favipiravir is safe and shows promising results regarding symptom resolution but does not improve viral clearance. The use of lopinavir/ritonavir has been associated with an increased risk of gastrointestinal adverse events and it has not proven to be effective. No significant differences were observed between patients treated with ribavirin or umifenovir and their respective control groups; Remdesivir and favipiravir are well tolerated and effective in accelerating clinical improvement. This systematic review does not support the use of lopinavir/ritonavir, ribavirin and umifenovir in hospitalized patients with COVID-19.

Links

PMC Free PDF

Authors+Show Affiliations

Gil Martínez V
Department of Pharmacology, Physiology and Legal and Forensic Medicine, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Avedillo Salas A
Department of Pharmacology, Physiology and Legal and Forensic Medicine, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.
Santander Ballestín S
Department of Pharmacology, Physiology and Legal and Forensic Medicine, Faculty of Medicine, University of Zaragoza, 50009 Zaragoza, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34451833

Citation

Gil Martínez, Victoria, et al. "Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: a Systematic Review." Pharmaceuticals (Basel, Switzerland), vol. 14, no. 8, 2021.
Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel). 2021;14(8).
Gil Martínez, V., Avedillo Salas, A., & Santander Ballestín, S. (2021). Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. Pharmaceuticals (Basel, Switzerland), 14(8). https://doi.org/10.3390/ph14080736
Gil Martínez V, Avedillo Salas A, Santander Ballestín S. Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: a Systematic Review. Pharmaceuticals (Basel). 2021 Jul 28;14(8) PubMed PMID: 34451833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. AU - Gil Martínez,Victoria, AU - Avedillo Salas,Ana, AU - Santander Ballestín,Sonia, Y1 - 2021/07/28/ PY - 2021/07/05/received PY - 2021/07/20/revised PY - 2021/07/23/accepted PY - 2021/8/28/entrez PY - 2021/8/29/pubmed PY - 2021/8/29/medline KW - COVID-19 KW - SARS-CoV-2 KW - antiviral KW - arbidol KW - efficacy KW - favipiravir KW - lopinavir/ritonavir KW - remdesivir KW - ribavirin KW - safety KW - treatment KW - umifenovir JF - Pharmaceuticals (Basel, Switzerland) JO - Pharmaceuticals (Basel) VL - 14 IS - 8 N2 - Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in developing new drugs, some drugs already approved for other diseases or with efficacy against SARS and MERS, have been used in patients with COVID-19. This systematic review aims to summarize evidence on the efficacy and safety of five antivirals applied to patients with COVID-19, that have proven to be effective either in vitro studies or in studies on SARS-CoV and MERS.; An intensive search of different databases (Pub Med, WoS, MEDLINE and Cochrane COVID-19 Study Register) has been carried out until the end of April 2021. This systematic review has been conducted according to the PRISMA statement. From each of the included studies, the characteristics of the intervention and comparison groups, demographic data and results were extracted independently; Remdesivir is well tolerated and helps to accelerate clinical improvement but is ineffective in reducing mortality. Favipiravir is safe and shows promising results regarding symptom resolution but does not improve viral clearance. The use of lopinavir/ritonavir has been associated with an increased risk of gastrointestinal adverse events and it has not proven to be effective. No significant differences were observed between patients treated with ribavirin or umifenovir and their respective control groups; Remdesivir and favipiravir are well tolerated and effective in accelerating clinical improvement. This systematic review does not support the use of lopinavir/ritonavir, ribavirin and umifenovir in hospitalized patients with COVID-19. SN - 1424-8247 UR - https://www.unboundmedicine.com/medline/citation/34451833/Antiviral_Therapeutic_Approaches_for_SARS_CoV_2_Infection:_A_Systematic_Review_ DB - PRIME DP - Unbound Medicine ER -